Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.61 USD
+0.21 (6.18%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.60 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 281 - 300 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financials; Looking Ahead to SITC and ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FATE Therapeutics 3Q18 Results; Platform Progress Heading into SITC 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ONO Collaboration Offers Path to Asia Markets
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FATE Therapeutics Announces Collaboration for Off-the-Shelf CAR-T Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of FATE shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results: Pipeline Continues to Progress, Looking to SITC and ASH for Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Financials; Looking Ahead to a Catalyst-Rich 2H18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results: FT500 IND Submission Expected 2Q18
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Financials; IND Submission for FT500 in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early APOLLO Update in Ovarian Cancer Shows Signs of Clinical Activity
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D